CLINICAL_TRIALS
trial_result
· 2021-11-24
Clinical Trial Update: Imaging of Coronary Plaques in Participants Treated With Evolocumab [Phase 3]
Summary
Phase 3 trial update evaluating imaging of coronary plaques in participants treated with evolocumab (AMG 232) in coronary artery disease.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Coronary Artery Disease (CAD) | Phase 3 | Status: COMPLETED | Results posted: 2021-11-24